Indiana Patent of the Month – February 2025
Sexton Biotechnologies has developed a groundbreaking method to enhance the safety and efficacy of platelet-based biologics. Their latest innovation leverages electron beam (e-beam) radiation to reduce pathogens in platelet lysates while preserving vital bioactive factors, addressing a critical challenge in regenerative medicine and cell therapy.
Traditional pathogen reduction methods often compromise the biological integrity of platelet-derived products, diminishing their therapeutic potential. Sexton Biotechnologies’ approach offers a sophisticated solution by subjecting frozen platelet lysates to e-beam radiation at energy levels between 5 MeV and 15 MeV, ensuring uniform exposure from multiple angles. This controlled process allows for effective pathogen inactivation while maintaining essential growth factors such as FGFb, EGF, PDGF-AB, PDGF-BB, and TGF-β.
A significant advantage of this technology is its ability to achieve at least a 3-Log reduction in viral contaminants, including Bovine Viral Diarrhea Virus, without compromising the structural and functional integrity of key proteins. Additionally, cooling during irradiation helps preserve the stability of these biologically active compounds. This results in a product with enhanced safety, making it highly suitable for cell culture applications, regenerative medicine, and clinical use.
By pioneering this pathogen reduction method, Sexton Biotechnologies is setting new standards in the biotechnology industry. Their innovative use of e-beam technology ensures that platelet-derived biologics remain both potent and pathogen-free, paving the way for safer and more effective treatments in cell therapy and regenerative medicine. This breakthrough underscores their commitment to advancing biomedical science and delivering high-quality, innovative solutions to the healthcare sector.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
